{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["81(5)"],"submitter":["Cid MC"],"funding":["Kiniksa Pharmaceuticals, Ltd."],"pubmed_abstract":["<h4>Objectives</h4>Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission.<h4>Methods</h4>This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary ef"],"journal":["Annals of the rheumatic diseases"],"pagination":["653-661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8995812"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial."],"pmcid":["PMC8995812"],"pubmed_authors":["Salvarani C","Dagna L","Trapnell BC","Unizony SH","Zhou T","Molloy E","Pupim L","KPL-301-C001 Investigators","Cid MC","Brouwer E","Wicks I","Paolini JF","Dasgupta B","Warrington KJ","Blockmans D","Hellmich B","Samant M"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.","description":"<h4>Objectives</h4>Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission.<h4>Methods</h4>This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary ef","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-06-07T07:33:42.426Z","creation":"2025-04-05T07:15:32.428Z"},"accession":"S-EPMC8995812","cross_references":{"pubmed":["35264321"],"doi":["10.1136/annrheumdis-2021-221865"]}}